We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Novel Test Offers New Accuracy Level in Heart Attack Diagnosis

By LabMedica International staff writers
Posted on 07 Oct 2025

Chest pain is one of the top reasons people visit emergency departments, yet only about one in ten patients presenting with these symptoms actually have a heart attack. More...

Emergency departments (EDs) face frequent overcrowding, making rapid, reliable triage critical to focus care where it is most needed. Now, a novel test has been shown to offer a new level of accuracy critical for diagnosing heart attacks.

Roche Diagnostics’ (Basel, Switzerland) test, Elecsys Troponin T hs Gen 6, is the latest advance in the company’s three-decade legacy of troponin innovation. The TSIX study program, a comprehensive global clinical effort involving more than 13,000 participants across the US, China, Japan, and the EU, highlighted the assay’s development and established robust reference limits for diverse populations. As part of that program, the REF-TSIX study derived 99th percentile upper reference limits (URLs) for the assay, which was 27 ng/L overall with sex-specific URLs of 18 ng/L for females and 32 ng/L for males, thus meeting the IFCC recommendations for clinical diagnostics.

To validate clinical performance, the PERFORM-TSIX prospective multicenter cohort enrolled 5,631 patients presenting with symptoms of acute coronary syndrome and collected up to five samples after ED presentation to assess test performance over time. The assay met its primary endpoint using the universal 99th percentile URL at three hours post presentation and supported early, safe rule-out: 56.6% of patients were able to be discharged within the first hours after presentation with a negative predictive value of 99.7%. These primary results were presented at the European Society for Emergency Medicine (EUSEM) and the European Society of Cardiology (ESC).

By improving sensitivity and precision, the assay supports faster, more reliable decision-making in emergency care and can reduce unnecessary admissions and diagnostic delay, helping health systems prioritize scarce resources. According to Roche, the Gen 6 test is the first in a series of anticipated approvals that will be paired with digital algorithms, near-patient devices, and laboratory analyzers to enable more standardized, point-of-care coronary artery disease (CAD) management worldwide. The company envisions this portfolio facilitating consistent biomarker measurement across settings and advancing next-generation acute coronary syndrome (ACS) offerings.

“Our new test enables clinicians to detect even the smallest elevations in troponin levels – a critical biomarker for heart attack – with high confidence,” said Matt Sause, Chief Executive Officer, Roche Diagnostics. “This ensures that in a situation when every second counts, patients receive the life-saving care they need at the earliest opportunity, and emergency services can prioritize resources to deliver care effectively to those in urgent need.”


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
8-Channel Pipette
SAPPHIRE 20–300 µL
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The TriVerity IVD test includes the TriVerity cartridge and the Myrna instrument (Photo courtesy of Inflammatix)

Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients

When a patient enters the emergency department in critical condition, clinicians must rapidly decide whether the patient has an infection, whether it is bacterial or viral, and whether immediate treatment... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.